<DOC>
	<DOCNO>NCT02318706</DOCNO>
	<brief_summary>Investigate efficacy safety DS-5565 subject Diabetic Peripheral Neuropathic Pain ( DPNP ) comparison placebo</brief_summary>
	<brief_title>DS-5565 Phase III Study Diabetic Peripheral Neuropathic Pain</brief_title>
	<detailed_description>[ Double Blind Phase ] The primary objective compare change Average Daily Pain Score ( ADPS ) baseline Week 14 Asian subject DPNP receive DS-5565 versus placebo . [ Open Extension Phase ] The objective ass long-term safety efficacy DS-5565 subject DPNP .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Type 1 type 2 diabetes mellitus screen Painful distal symmetric polyneuropathy At screening , pain scale â‰¥ 40 mm HbA1c ( National Glycohemoglobin Standardization Program ) &gt; 10.0 %</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic Peripheral Neuropathic Pain</keyword>
</DOC>